ClinicalTrials.gg
RecruitingNCT06051123PROBIOTICUpdated Sep 17, 2026

Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients

An interventional study of Probiotic and Placebo in ALSFTD, ALS (Amyotrophic Lateral Sclerosis) and Frontal Temporal Dementia (FTD), sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada — 15 open to participants now, 25 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Canada.

Planned enrollment
24th of 72
150 · median 75
Started
2024
with 8 others
No phase
7 of 82
3 open now
Primary completion
2027-02
later than 8 of 24 live
Registered
65th of 82
by date

Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, this one is the 24th largest by planned enrollment of the 72 interventional ones that give a count, is one of 9 that started in 2024, is one of 7 with no phase, reaches primary completion later than 8 of the 24 other live ones, and was the 65th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

15 of the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

The aim of this study is to assess the impact of a probiotic formulation on participants with ALS-FTDSD. It is hypothesized that participants given the probiotics will have different lipid profiles compared to participants receiving the placebo at different time points.

Read the detailed description

Individuals with ALS-FTDSD, their caregivers and healthy individuals can participate in this randomized, double-blind, parallel, placebo-controlled study. Participants will be enrolled for a period of 32 weeks, with an intervention period of 24 weeks. For ALS-FTDSD participants, there will be 9 visits during the intervention (5 in-person and 4 phone calls) and 1 follow-up call post-intervention. For healthy participants, there will be 4 in-person visits. For all participants, in-person visits will involve filling out questionnaires, giving blood samples, and returning stool samples.

03

Conditions studied

  • ALSFTD
  • ALS (Amyotrophic Lateral Sclerosis)
  • Frontal Temporal Dementia (FTD)

Keywords

  • ALS
  • FTD
  • motor function
  • probiotics
  • lipidomics
  • metabolites
  • neurofilament
  • microbiome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following inclusion criteria to be eligible for enrolment into the study:ALS-FTDSD participants

  1. Aged 18 years old or greater.
  2. Diagnosis of ALS by El Escorial Criteria revised (possible, probable, probable with lab support and definite).
  3. Onset of weakness or speech impairment no more than 24 months before randomization.
  4. ALSFRS-R equal or superior to 24/48 at screening, with no more than one subscore under 2/4.
  5. SVC greater than or equal to 60% predicted for sex, age and height at screening.
  6. Note on FTD Symptoms: The presence of FTD symptoms is not a requirement for inclusion in this study. Participants with a diagnosis of ALS, whether or not accompanied by FTD symptoms, are eligible for inclusion. No prior or screening diagnosis of FTDSD is required.
  7. Subject has an informant/caregiver who has frequent and sufficient contact to provide accurate information about the patient's cognitive abilities and behaviors to complete the ALS-CBS.
  8. Participants apt to comprehend and sign the ICF.
  9. Participants of must have a negative serum pregnancy test at screening and agree to use a medically approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

    • Abstinence or agrees to use contraception if planning to become sexually active.
    • Hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant
    • Double-barrier method
    • Intrauterine devices
    • Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
    • Vasectomy of partner at least 6 months prior to screening
  10. Willing to maintain eating habits throughout the study.
  11. Willing to refrain from consuming probiotic supplements and food containing added probiotics and/or prebiotics (e.g., yogurts with live, active cultures or supplements) from the moment of screening until the end of the study.

Healthy controls:

  1. Aged 18 years old or greater.
  2. Able to comprehend and willing to sign ICF.
  3. Participants of child-bearing potential must have a negative serum pregnancy test at screening and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

    • Abstinence or agrees to use contraception if planning to become sexually active.
    • Hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant
    • Double-barrier method
    • Intrauterine devices
    • Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
    • Vasectomy of partner at least 6 months prior to screening
  4. Willing to maintain eating habits throughout the study.
  5. Willing to refrain from consuming probiotic supplements and food containing added probiotics and/or prebiotics (e.g., yogurts with live, active cultures or supplements) from the moment of screening until the end of the study.

Informant/caregiver

  1. Aged 18 years old or greater.
  2. Has frequent and sufficient contact to provide accurate information about the patient's cognitive abilities and behaviors to complete the ALS-CBS.
  3. Able to comprehend and willing to sign ICF

Exclusion criteria

Exclusion criteria:

Subjects with any of the following characteristics/conditions will not be included in the study:

ALS-FTDSD participants

  1. Use of respiratory support (non-invasive ventilation or mechanical respiratory support) at screening.
  2. Significant medical condition or behavioral issues that could interfere with participation in the clinical trial in the principal investigator's opinion.
  3. Use of a feeding tube at randomization.
  4. Use of lipid-lowering drugs for less than 3 months before randomization.
  5. Introduction of lipid-lowering drug unless it is due to the event of acute coronary syndrome or stroke as per Canadian guidelines.
  6. Use of edaravone with stable dosage for less than 2 months before randomization.
  7. Use of riluzole with stable dosage for less than 1 month before randomization.
  8. Introduction of edaravone or riluzole during the clinical trial.
  9. Immunodeficiency (immune-compromised and immune-suppressed participants, e.g., AIDS, lymphoma, participants undergoing long-term treatment, chemotherapy and allograft participants).
  10. Pregnancy (as per serum HCG pregnancy test at screening), planning to be pregnant or currently breastfeeding.
  11. Use of probiotics other than the study medication in the month prior to randomization. Note: participants could be eligible to participate after a 4-week .
  12. Use of any antibiotic drug in the month prior to randomization. Note: participants could be eligible to participate after a 4-week washout period.
  13. Milk and soy allergy, or severe lactose intolerance.
  14. Currently enrolled in another clinical trial.

Healthy controls:

  1. Use of lipid-lowering drugs for less than 3 months before randomization.
  2. Introduction of lipid-lowering drug unless it is due to the event of acute coronary syndrome or stroke as per Canadian guidelines.
  3. Pregnancy (as per serum HCG pregnancy test at screening), planning to be pregnant or currently breastfeeding. Note: participants will not take the IP or placebo, but pregnancy is a major factor that could affect lipidomic profiling.
  4. Use of probiotics in the month prior to day 0 of the study (visit 2). Note: participants could be eligible to participate after a 4-week washout period. Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group.
  5. Use of any antibiotic drug in the month prior to day 0 of the study (visit 2). Note: participants could be eligible to participate after a 4-week washout period. Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group.
  6. Milk and soy allergy, or severe lactose intolerance. Note: Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group. We aim to exclude allergies, so participants are maintained on standard diet.
  7. Currently enrolled in another clinical trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Participants in this group will be randomized to receive a probiotic formulation for 24 weeks.

    Dietary Supplement: Probiotic

  • Placebo comparator
    Control Group

    Participants in this group will be randomized to receive a placebo for 24 weeks.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementProbiotic

    Participants will be taking 1 sachet a day.

  • Dietary supplementPlacebo

    Participants will be taking 1 sachet a day.

06

What researchers measure

Primary outcomes

  1. Change in lipids and polar metabolites composition in the plasma of participant

    Metabolomics will provide a quantitative and qualitative assesment of the lipidomic and polar metabolite profiles of participants on the probiotic arm and the participants on the placebo arm. Participants will be assessed at week 0, at week 12 and then at the end of the investigation period at week 24.

    Time frame: 24 weeks

Secondary outcomes

  1. Change in ALS Functional Rating Scale Revised (ALSFRS-R) score

    Participants' ALS Functional Rating Scale Revised (ALSFRS-R) score, following intake of the probiotic or placebo. Participants will be assessed at week 0, at week12 and then at the end of the investigation period at week 24.

    Time frame: 24 weeks

  2. Change in ALS-CBS score

    To compare the average change from baseline in ALS Cognitive Behavioral Screen (ALS-CBS) and Frontal Assessment Battery (FAB) between the probiotic and placebo groups over the 24 weeks of intervention.

    Time frame: 24 weeks

  3. Change in neurofilament light chain concentration

    To compare the average change from baseline in the neurofilament light chain concentration between the probiotic and placebo groups over the 24 weeks of intervention.

    Time frame: 24 weeks

  4. Change in ALSAQ-5 scores

    To compare the average change from baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5 (ALSAQ-5) between the probiotic and placebo groups over the 24 weeks of intervention.

    Time frame: 24 weeks

  5. Change in fecal microbiota in ALS-FTDSD patients

    To compare the fecal microbiota composition, diversity, and strain recovery over the 24 weeks of intervention in the probiotic and placebo groups. Techniques will be based on the extraction of DNA and amplification of 16S ribosomal RNA genes. These genes are highly conserved between bacterial species, but vary in a manner that allows species identification.

    Time frame: 24 weeks

  6. Lipidomic profiles of healthy participants

    To explore lipidomic profiles from baseline in healthy participants over the 24 weeks of intervention. This will be a lipid profiling and quantification by using mass-spectrometry-based lipidomics. We are going to test 900 different lipids, which can be classified in 20 classes ans subclasses of interest.

    Time frame: 24 weeks

Other outcomes

  1. Number of AEs and SAEs

    To compare the number of adverse events (AEs) and serious adverse events (SAEs) that occur among to the probiotic group versus the placebo group throughout the study.

    Time frame: 28 weeks

  2. Changes in lab safety marker: Complete Blood Count (CBC)

    Changes (outside normal variation) in safety lab marker: Complete Blood Count (CBC).

    Time frame: 24 weeks

  3. Changes in lab safety markers: Liver Function Test (LFT) - ALT

    Changes (outside normal variation) in safety lab markers :Liver Function Tests (LFTs), more precisely alanine transaminase (ALT).

    Time frame: 24 weeks

  4. Changes in lab safety markers: Liver Function Test (LFT) - AST

    Changes (outside normal variation) in safety lab markers :Liver Function Tests (LFTs), more precisely aspartate transaminase (AST).

    Time frame: 24 weeks

  5. Changes in lab safety markers: Liver Function Test (LFT) - bilirubin

    Changes (outside normal variation) in safety lab markers :Liver Function Tests (LFTs), more precisely total bilirubin.

    Time frame: 24 weeks

  6. Changes in lab safety marker: creatinine

    Changes (outside normal variation) in safety lab marker: creatinine.

    Time frame: 24 weeks

07

Study locations

3 of 3 sites recruiting
  • Stan Cassidy Centre for Rehabilitation
    Fredericton, New Brunswick E3B 0C7, Canada
    Recruiting
    • Susan McCully, RN MN · ContactSusan.mccully@horizonnb.ca · (506) 471-9924
    • Colleen O'Connell, MD, FRCPC · Principal investigator
  • Centre Hospitalier de l'Université de Montréal
    Montreal, Quebec H2X 0A9, Canada
    Recruiting
  • University of Saskatchewan, Clinical Trials Support Unit
    Saskatoon, Saskatchewan S7N 0W8, Canada
    Recruiting
    • Janet Peters, Clinical Research Coordinator, RN · Contactjanet.peters@usask.ca · +1 639 317 5899
    • Joanne Boyer, RN · Contactjoanne.boyer@usask.ca · +1 306 280 8001
    • Kerri Schellenberg, MD, FRCPC · Principal investigator
    • Ryan Verity, MD, FRCPC, CSCN · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Feb 2027, 37 months after the start.

Of 134 non-industry interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 37 months is close to that.

Counting every sponsor, half of 154 studies reached it within 35 months; a quarter within 23 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2023
First posted
Sep 22, 2023
StartActual
Jan 1, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06051123
Collaborators
Lallemand Health Solutions
Responsible party
Sponsor
First posted
Sep 22, 2023
Start date
Jan 1, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Amélie Bujold, RN
Contact
amelie.bujold.chum@ssss.gouv.qc.ca
514-890-8000 ext. 13616
Richard Miallot, PhD
Contact
richard.miallot.chum@ssss.gouv.qc.ca
514-890-8000 ext. 13616
Genevieve Matte, MDCM, FRCP
principal investigator · CRCHUM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion